Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07600151CT.gov Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07285239CT.gov Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07029776CT.gov MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07428369CT.gov A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Withdrawn | — | — | — |
NCT07341867CT.gov Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype | — | Not Yet Recruiting | — | — | — |
NCT07649525CT.gov Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level | — | Not Yet Recruiting | — | — | — |
NCT07247097CT.gov ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT07334535CT.gov Isa-VRD in TIE HRMM | — | Not Yet Recruiting | — | — | — |
NCT07095452CT.gov A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT07297329CT.gov A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Recruiting | — | — | — |
Show 385 more trialsShow fewer
NCT06932562CT.gov A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | — | Recruiting | — | — | — |
NCT06910124CT.gov Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | — | Recruiting | — | — | — |
NCT07149857CT.gov A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | — | Recruiting | — | — | — |
NCT06997081CT.gov ERd Combination Treatment in Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT07018050CT.gov Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma | — | Recruiting | — | — | — |
NCT07210047CT.gov Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | — | Enrolling By Invitation | — | — | — |
NCT06974786CT.gov Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma | — | Recruiting | — | — | — |
NCT07099391CT.gov A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06918002CT.gov Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients | — | Recruiting | — | — | — |
NCT07045909CT.gov Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | — | Recruiting | — | — | — |
NCT06892522CT.gov A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | — | Recruiting | — | — | — |
NCT06461988CT.gov Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | — | Recruiting | — | — | — |
NCT06931704CT.gov Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA) | — | Not Yet Recruiting | — | — | — |
NCT06799676CT.gov A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT06744894CT.gov SIL as Maintenance Therapy in Multiple Myeloma | — | Not Yet Recruiting | — | — | — |
NCT06679101CT.gov A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | — | Recruiting | — | — | — |
NCT06768489CT.gov A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma | — | Recruiting | — | — | — |
NCT05846880CT.gov VitD3 Supplementation in Patients With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06577025CT.gov A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04876248CT.gov Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant | — | Active Not Recruiting | — | — | — |
NCT06169215CT.gov Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06207799CT.gov Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT06353022CT.gov Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06505369CT.gov Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT06409702CT.gov Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection | — | Recruiting | — | — | — |
NCT06042725CT.gov MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma | — | Recruiting | — | — | — |
NCT05820763CT.gov Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant | — | Withdrawn | — | — | — |
NCT06163040CT.gov A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan | — | Completed | — | — | — |
NCT05572229CT.gov Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma | — | Recruiting | — | — | — |
NCT05231629CT.gov Sequential Therapy in Multiple Myeloma Guided by MRD Assessments | — | Recruiting | — | — | — |
NCT06158269CT.gov DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | — | Recruiting | — | — | — |
NCT05583617CT.gov A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma | — | Recruiting | — | — | — |
NCT06140966CT.gov Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT06045806CT.gov A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT05257083CT.gov A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT06050512CT.gov Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT05849610CT.gov Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03759093CT.gov CURATE.AI Optimized Modulation for Multiple Myeloma | — | Unknown | — | — | — |
NCT05776979CT.gov Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT05573802CT.gov A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05690984CT.gov Elimination of Minimal Residual Disease After Transplant | — | Active Not Recruiting | — | — | — |
NCT05827016CT.gov A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05850286CT.gov A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities | — | Active Not Recruiting | — | — | — |
NCT05804032CT.gov Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT05669989CT.gov International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | — | Active Not Recruiting | — | — | — |
NCT05860036CT.gov A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05675319CT.gov Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy | — | Terminated | — | — | — |
NCT05641324CT.gov A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | — | Terminated | — | — | — |
NCT05665140CT.gov Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT05556616CT.gov A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | — | Terminated | — | — | — |
NCT05344833CT.gov Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma | — | Recruiting | — | — | — |
NCT05438043CT.gov A Study of Daratumumab | — | Recruiting | — | — | — |
NCT06209606CT.gov Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | — | Recruiting | — | — | — |
NCT05695508CT.gov GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | — | Recruiting | — | — | — |
NCT05091372CT.gov Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05623020CT.gov A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant | — | Recruiting | — | — | — |
NCT05552222CT.gov A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT05259839CT.gov A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05558319CT.gov NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | — | Not Yet Recruiting | — | — | — |
NCT05497804CT.gov Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | — | Active Not Recruiting | — | — | — |
NCT05243797CT.gov Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | — | Recruiting | — | — | — |
NCT05137054CT.gov A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | — | Recruiting | — | — | — |
NCT05469893CT.gov Immuno-PRISM (PRecision Intervention Smoldering Myeloma) | — | Recruiting | — | — | — |
NCT05495620CT.gov Long-term KRd in Relapsed and/or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT05422027CT.gov Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT07150091CT.gov Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | — | Active Not Recruiting | — | — | — |
NCT05900882CT.gov SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease | — | Recruiting | — | — | — |
NCT05722405CT.gov Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma | — | Recruiting | — | — | — |
NCT05183139CT.gov A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT05288062CT.gov Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | — | Terminated | — | — | — |
NCT05308654CT.gov A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | — | Active Not Recruiting | — | — | — |
NCT05280275CT.gov A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | — | Unknown | — | — | — |
NCT05123131CT.gov Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT05147493CT.gov A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | — | Unknown | — | — | — |
NCT05317416CT.gov Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant | — | Active Not Recruiting | — | — | — |
NCT05145400CT.gov Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma | — | Recruiting | — | — | — |
NCT03941860CT.gov Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial | — | Completed | — | — | — |
NCT04941937CT.gov Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM | — | Unknown | — | — | — |
NCT05032820CT.gov Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | — | Completed | — | — | — |
NCT04942067CT.gov APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04998786CT.gov A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | — | Active Not Recruiting | — | — | — |
NCT04223661CT.gov Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy | — | Withdrawn | — | — | — |
NCT05497102CT.gov Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT | — | Unknown | — | — | — |
NCT05090566CT.gov MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma | — | Terminated | — | — | — |
NCT04234022CT.gov Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma | — | Recruiting | — | — | — |
NCT04891809CT.gov Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | — | Active Not Recruiting | — | — | — |
NCT05050097CT.gov A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04782687CT.gov Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04923893CT.gov A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy | — | Active Not Recruiting | — | — | — |
NCT04717700CT.gov Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients | — | Active Not Recruiting | — | — | — |
NCT04751877CT.gov Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years). | — | Active Not Recruiting | — | — | — |
NCT04653246CT.gov Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM | — | Active Not Recruiting | — | — | — |
NCT04939844CT.gov REST - Replacing Steroids in the Transplant Ineligble | — | Completed | — | — | — |
NCT04892264CT.gov Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma | — | Terminated | — | — | — |
NCT04822337CT.gov Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04818372CT.gov Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma | — | Unknown | — | — | — |
NCT04674514CT.gov APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT04802356CT.gov Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT04722146CT.gov A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04519476CT.gov Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | — | Unknown | — | — | — |
NCT04009109CT.gov Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM | — | Active Not Recruiting | — | — | — |
NCT04483739CT.gov Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL) | — | Active Not Recruiting | — | — | — |
NCT04277845CT.gov Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT03720041CT.gov Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma | — | Unknown | — | — | — |
NCT04405167CT.gov Tasquinimod for the Treatment of Relapsed or Refractory Myeloma | — | Terminated | — | — | — |
NCT04430894CT.gov KRDI in Transplant-Eligible MM | — | Active Not Recruiting | — | — | — |
NCT03959358CT.gov A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | — | Completed | — | — | — |
NCT04270409CT.gov Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04196491CT.gov A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | — | Completed | — | — | — |
NCT04352205CT.gov Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure | — | Terminated | — | — | — |
NCT04119336CT.gov Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma | — | Terminated | — | — | — |
NCT04268498CT.gov A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04113018CT.gov Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04091126CT.gov Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04151667CT.gov Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04174196CT.gov A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | — | Active Not Recruiting | — | — | — |
NCT04133636CT.gov A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04052880CT.gov Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | — | Active Not Recruiting | — | — | — |
NCT04028115CT.gov Bone Healing During Ninlaro Exposure | — | Completed | — | — | — |
NCT03993912CT.gov Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy | — | Active Not Recruiting | — | — | — |
NCT04126200CT.gov Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03608501CT.gov A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation | — | Withdrawn | — | — | — |
NCT04217967CT.gov Ixazomib, Lenalidomide, and Combination for Maintenance in NDMM Patients | — | Completed | — | — | — |
NCT03376477CT.gov Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | — | Terminated | — | — | — |
NCT04094961CT.gov Ixazomib + Pomalidomide + Dexamethasone In MM | — | Active Not Recruiting | — | — | — |
NCT03934684CT.gov Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03702725CT.gov Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04071457CT.gov S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration | — | Active Not Recruiting | — | — | — |
NCT04068597CT.gov Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | — | Recruiting | — | — | — |
NCT03606577CT.gov An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT03984097CT.gov A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM) | — | Completed | — | — | — |
NCT03836014CT.gov Study Comparing Continuous Versus Fixed Duration Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04025450CT.gov Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients | — | Recruiting | — | — | — |
NCT03942224CT.gov Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT04096066CT.gov A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | — | Active Not Recruiting | — | — | — |
NCT03815279CT.gov A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | — | Enrolling By Invitation | — | — | — |
NCT03856112CT.gov Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03859427CT.gov A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03729804CT.gov Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | — | Active Not Recruiting | — | — | — |
NCT03903406CT.gov Quality of Life, Symptoms and Treatment Satisfaction in Adult Patients With Relapsed and/or Refractory Multiple Myeloma, Receiving Ixazomib (Ninlaro®) in Combination With Lenalidomide and Dexamethasone in a Real World Setting: Pilot Study | — | Unknown | — | — | — |
NCT03785184CT.gov A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy | — | Withdrawn | — | — | — |
NCT03651128CT.gov Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | — | Active Not Recruiting | — | — | — |
NCT03908138CT.gov RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma | — | Unknown | — | — | — |
NCT03952091CT.gov TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03733691CT.gov Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients | — | Terminated | — | — | — |
NCT03500445CT.gov Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03748953CT.gov Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) | — | Completed | — | — | — |
NCT03763162CT.gov Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03829371CT.gov STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA | — | Active Not Recruiting | — | — | — |
NCT03669445CT.gov Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma | — | Unknown | — | — | — |
NCT03710603CT.gov Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03601078CT.gov An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | — | Completed | — | — | — |
NCT03742297CT.gov Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years | — | Active Not Recruiting | — | — | — |
NCT03617731CT.gov Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) | — | Active Not Recruiting | — | — | — |
NCT03590652CT.gov Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03411031CT.gov Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | — | Terminated | — | — | — |
NCT03544281CT.gov To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03948035CT.gov Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM | — | Active Not Recruiting | — | — | — |
NCT07206810CT.gov A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT03605056CT.gov Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM | — | Unknown | — | — | — |
NCT03506802CT.gov TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03556332CT.gov A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation | — | Active Not Recruiting | — | — | — |
NCT03031730CT.gov Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | — | Terminated | — | — | — |
NCT03376672CT.gov Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT04065789CT.gov Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients | — | Completed | — | — | — |
NCT03412565CT.gov A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens | — | Completed | — | — | — |
NCT03433001CT.gov A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone | — | Completed | — | — | — |
NCT03492138CT.gov Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT03314636CT.gov Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment. | — | Active Not Recruiting | — | — | — |
NCT03224507CT.gov Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma | — | Completed | — | — | — |
NCT03439293CT.gov A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | Completed | — | — | — |
NCT03416374CT.gov A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy | — | Completed | — | — | — |
NCT03413800CT.gov Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | — | Completed | — | — | — |
NCT03100877CT.gov Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03319667CT.gov A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | — | Active Not Recruiting | — | — | — |
NCT03269136CT.gov PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT03173092CT.gov A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | — | Terminated | — | — | — |
NCT04287660CT.gov Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients | — | Unknown | — | — | — |
NCT03283046CT.gov Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03168100CT.gov 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | — | Withdrawn | — | — | — |
NCT03290950CT.gov A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03104842CT.gov Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | — | Active Not Recruiting | — | — | — |
NCT03170882CT.gov A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma | — | Completed | — | — | — |
NCT03191981CT.gov Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT02969837CT.gov Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma | — | Completed | — | — | — |
NCT03004287CT.gov 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy | — | Active Not Recruiting | — | — | — |
NCT03015922CT.gov Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT02802163CT.gov Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat | — | Withdrawn | — | — | — |
NCT03169361CT.gov NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" | — | Completed | — | — | — |
NCT03225417CT.gov Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. | — | Active Not Recruiting | — | — | — |
NCT03150316CT.gov CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma | — | Unknown | — | — | — |
NCT03012880CT.gov Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02334865CT.gov SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy | — | Active Not Recruiting | — | — | — |
NCT03000634CT.gov 2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy | — | Withdrawn | — | — | — |
NCT03106324CT.gov A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant | — | Completed | — | — | — |
NCT04063189CT.gov Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone in the Treatment of the First Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT02891811CT.gov Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy | — | Completed | — | — | — |
NCT03015792CT.gov Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | — | Terminated | — | — | — |
NCT03070327CT.gov BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03110822CT.gov A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | — | Recruiting | — | — | — |
NCT02924272CT.gov Ixazomib Rollover Study | — | Completed | — | — | — |
NCT02906332CT.gov Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM) | — | Terminated | — | — | — |
NCT02986451CT.gov Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma | — | Withdrawn | — | — | — |
NCT02917941CT.gov A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02937571CT.gov High Dose Carfilzomib for Newly Diagnosed Myeloma | — | Completed | — | — | — |
NCT02843074CT.gov Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02880228CT.gov Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant | — | Completed | — | — | — |
NCT02765854CT.gov Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement | — | Completed | — | — | — |
NCT02897830CT.gov Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma | — | Terminated | — | — | — |
NCT02719613CT.gov Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | — | Completed | — | — | — |
NCT02831686CT.gov A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma | — | Completed | — | — | — |
NCT02728102CT.gov Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401) | — | Completed | — | — | — |
NCT02720510CT.gov A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | — | Terminated | — | — | — |
NCT02659293CT.gov Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02685826CT.gov A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02697344CT.gov Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT02492750CT.gov Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | — | Completed | — | — | — |
NCT02516696CT.gov BiRd vs. Rd as Initial Therapy in Multiple Myeloma | — | Terminated | — | — | — |
NCT02655458CT.gov Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma | — | Completed | — | — | — |
NCT02619682CT.gov Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02461888CT.gov Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma. | — | Completed | — | — | — |
NCT02578121CT.gov UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination | — | Withdrawn | — | — | — |
NCT02426723CT.gov Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | — | Completed | — | — | — |
NCT02579863CT.gov Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | — | Terminated | — | — | — |
NCT02343042CT.gov Selinexor and Backbone Treatments of Multiple Myeloma Patients | — | Active Not Recruiting | — | — | — |
NCT02513186CT.gov Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation | — | Completed | — | — | — |
NCT02499081CT.gov UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | — | Completed | — | — | — |
NCT02575144CT.gov GEM-CLARIDEX: Ld vs BiRd | — | Unknown | — | — | — |
NCT02440464CT.gov Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) | — | Completed | — | — | — |
NCT02412228CT.gov Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma | — | Completed | — | — | — |
NCT02431208CT.gov A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT02389543CT.gov Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients | — | Withdrawn | — | — | — |
NCT02495922CT.gov A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma | — | Completed | — | — | — |
NCT02331368CT.gov Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | — | Completed | — | — | — |
NCT02375555CT.gov Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | — | Completed | — | — | — |
NCT02335983CT.gov Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT02420860CT.gov Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02312258CT.gov A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) | — | Completed | — | — | — |
NCT02410694CT.gov Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02389517CT.gov Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant | — | Completed | — | — | — |
NCT02272803CT.gov Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | — | Completed | — | — | — |
NCT02252172CT.gov Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02203643CT.gov Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma. | — | Completed | — | — | — |
NCT02253316CT.gov Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02294357CT.gov Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib | — | Terminated | — | — | — |
NCT01936532CT.gov Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06) | — | Completed | — | — | — |
NCT02406144CT.gov Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma | — | Completed | — | — | — |
NCT02219178CT.gov Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT02206425CT.gov Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02128230CT.gov UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | — | Terminated | — | — | — |
NCT01861340CT.gov Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT02159365CT.gov Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients | — | Completed | — | — | — |
NCT02046070CT.gov Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02077959CT.gov Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01794039CT.gov Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | — | Completed | — | — | — |
NCT01998971CT.gov A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT02036502CT.gov A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | — | Terminated | — | — | — |
NCT02405364CT.gov Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction | — | Completed | — | — | — |
NCT02030483CT.gov Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma | — | Terminated | — | — | — |
NCT02004275CT.gov Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Relapsed Multiple Myeloma | — | Unknown | — | — | — |
NCT02086552CT.gov Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01927718CT.gov Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | — | Terminated | — | — | — |
NCT01863550CT.gov Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT01985477CT.gov Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01953692CT.gov A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | — | Completed | — | — | — |
NCT01919619CT.gov Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | — | Completed | — | — | — |
NCT01947309CT.gov Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide) | — | Terminated | — | — | — |
NCT01881789CT.gov Oprozomib and Dexamethasone,in Combination With Lenalidomide or Oral Cyclophosphamide to Treat Newly Diagnosed Multiple Myeloma | — | Terminated | — | — | — |
NCT01965353CT.gov A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01891643CT.gov PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy) | — | Terminated | — | — | — |
NCT01830816CT.gov Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment | — | Completed | — | — | — |
NCT01729091CT.gov Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01619761CT.gov NK Cells in Cord Blood Transplantation | — | Unknown | — | — | — |
NCT01850524CT.gov IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01827137CT.gov WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | — | Completed | — | — | — |
NCT01440582CT.gov Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients | — | Completed | — | — | — |
NCT01749969CT.gov SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients | — | Completed | — | — | — |
NCT01816971CT.gov Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01729338CT.gov Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | — | Terminated | — | — | — |
NCT01645930CT.gov Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01718743CT.gov Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01755975CT.gov Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | — | Completed | — | — | — |
NCT01668719CT.gov S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | — | Completed | — | — | — |
NCT01742793CT.gov An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) | — | Terminated | — | — | — |
NCT01731886CT.gov Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01564537CT.gov A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01583283CT.gov Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | — | Completed | — | — | — |
NCT01651039CT.gov Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01615029CT.gov Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04272775CT.gov A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | Terminated | — | — | — |
NCT01537861CT.gov Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT01572480CT.gov Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | — | Completed | — | — | — |
NCT01531998CT.gov Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT01562405CT.gov Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT01559935CT.gov Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT01374217CT.gov Administration of Tadalafil in Conjunction With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma | — | Terminated | — | — | — |
NCT01555281CT.gov Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | — | Terminated | — | — | — |
NCT01518465CT.gov Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | — | Terminated | — | — | — |
NCT01393964CT.gov Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function | — | Completed | — | — | — |
NCT01501370CT.gov Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy | — | Withdrawn | — | — | — |
NCT01349569CT.gov Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission | — | Completed | — | — | — |
NCT01502085CT.gov Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens | — | Completed | — | — | — |
NCT01460420CT.gov Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation | — | Completed | — | — | — |
NCT01383928CT.gov Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01359657CT.gov Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01335399CT.gov Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT01348919CT.gov Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01352338CT.gov Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) | — | Completed | — | — | — |
NCT01402284CT.gov Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01421186CT.gov A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01055301CT.gov S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | — | Withdrawn | — | — | — |
NCT01335685CT.gov Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01239797CT.gov Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01245673CT.gov Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma | — | Completed | — | — | — |
NCT01297764CT.gov A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT02556905CT.gov A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea | — | Completed | — | — | — |
NCT01450215CT.gov Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | — | Completed | — | — | — |
NCT01303965CT.gov Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | — | Terminated | — | — | — |
NCT01237249CT.gov Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | — | Completed | — | — | — |
NCT01208766CT.gov Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01752075CT.gov A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan | — | Completed | — | — | — |
NCT01217957CT.gov A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT01215344CT.gov First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | — | Completed | — | — | — |
NCT01242930CT.gov Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT01217203CT.gov Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse | — | Completed | — | — | — |
NCT01142232CT.gov Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma | — | Completed | — | — | — |
NCT01080391CT.gov Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT01155583CT.gov Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT01109004CT.gov Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) | — | Completed | — | — | — |
NCT01554852CT.gov Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients | — | Unknown | — | — | — |
NCT01621672CT.gov UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT01090089CT.gov Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma | — | Completed | — | — | — |
NCT01038388CT.gov A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00932698CT.gov Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma | — | Completed | — | — | — |
NCT01093196CT.gov Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients | — | Completed | — | — | — |
NCT01010243CT.gov Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial | — | Unknown | — | — | — |
NCT01029054CT.gov Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT01002703CT.gov Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | — | Unknown | — | — | — |
NCT01160484CT.gov Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00966693CT.gov Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00925821CT.gov Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00902915CT.gov Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure | — | Unknown | — | — | — |
NCT00698776CT.gov Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | — | Completed | — | — | — |
NCT00778752CT.gov Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | — | Completed | — | — | — |
NCT00790842CT.gov Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction | — | Terminated | — | — | — |
NCT01530594CT.gov Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00729118CT.gov Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00689936CT.gov Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00687674CT.gov Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00691704CT.gov Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy | — | Completed | — | — | — |
NCT01160107CT.gov Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00729638CT.gov RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00560391CT.gov Dasatinib in Combination With Revlimid (and Dexamethasone) | — | Completed | — | — | — |
NCT00603447CT.gov Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT00724568CT.gov Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00532675CT.gov Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | — | Completed | — | — | — |
NCT00642954CT.gov Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | — | Completed | — | — | — |
NCT01042704CT.gov Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | — | Completed | — | — | — |
NCT00617591CT.gov Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00538824CT.gov Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma | — | Terminated | — | — | — |
NCT00538733CT.gov Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma | — | Completed | — | — | — |
NCT00507442CT.gov Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients | — | Completed | — | — | — |
NCT00525447CT.gov Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00398515CT.gov Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma | — | Completed | — | — | — |
NCT00961467CT.gov RMPT for Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00445692CT.gov Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma | — | Completed | — | — | — |
NCT00445484CT.gov Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00405756CT.gov A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | — | Completed | — | — | — |
NCT00415064CT.gov Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | — | Completed | — | — | — |
NCT00396045CT.gov Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | — | Completed | — | — | — |
NCT00151203CT.gov Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | — | Completed | — | — | — |
NCT00098475CT.gov Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT00306813CT.gov Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00153933CT.gov Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00093028CT.gov Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | — | Completed | — | — | — |
NCT00065351CT.gov Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00622336CT.gov A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT00091624CT.gov A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | — | Completed | — | — | — |
NCT00056160CT.gov CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT00424047CT.gov A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | — | Completed | — | — | — |
NCT00051116CT.gov A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT00044018CT.gov CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT02856438CT.gov Early Patient Access Treatment Use Protocol CA204-220 | — | No Longer Available | — | — | — |
NCT02666209CT.gov Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma | — | No Longer Available | — | — | — |
NCT02368301CT.gov Expanded Access Treatment Protocol CA204-143 | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | Universitätsklinikum Hamburg-Eppendorf | Approved | BB · 69 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 9, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →